Wilson Disease Drugs Market
Global Wilson Disease Drugs Market Size, Share and Trends Analysis Report, By Drug Type (Chelating Agents, Zinc, and Tetrathiomolybdate), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Forecast Period (2022-2028)
The global Wilson disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period. The market is anticipated to accelerate during the forecast period, owing to the emergence of several international and regional drug manufacturers that provides drugs such as chelators and minerals for Wilson treatment. Moreover, new drug launches by the key players are one of the prominent factors boosting the market growth. For instance, in August 2021, AstraZeneca’s Alexion rare disease unit cleared a phase 3 trial of ALXN1840 for the treatment of Wilson's disease. ALXN1840 improved copper mobilization from tissues. ALXN1840 was more than three times more effective than the standard treatment in mobilizing copper from tissues. In addition, limited infrastructural facilities and a lack of awareness in backward economies are expected to obstruct market growth. Additionally, the growing application of genetic testing in oncology and genetic diseases, coupled with the growing demand for direct-to-consumer testing has created a lucrative opportunity in coming years in the global Wilson disease drugs market.
Segmental Outlook
The global Wilson disease drugs market is segmented based on drug type, route of administration, and distribution channel. Based on drug type, the market is segmented into chelating agents, zinc, and tetrathiomolybdate. Based on the route of administration, the market is segmented into oral, parenteral, and others. Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others.
Penicillamine (Cupramine and Depen) and trientine (Syprine) are two chelating agents that are used for the treatment of Wilson's disease. Such medications remove copper from the body. However, Penicillamine may cause side effects compared to trientine. penicillamine side effects may include kidney problems, rash, fever, or bone marrow problems. Penicillamine may also decrease the activity of vitamin B6, and thus, vitamin B6 supplements may be recommended by the doctors along with penicillamine. Moreover, zinc prevents the intestines from absorbing copper. Zinc may be prescribed by the doctor as a maintenance treatment after chelating agents have removed extra copper from the body. In addition, doctors may also recommend zinc for people with Wilson's disease, however, who do not yet have symptoms. Stomach upset is the most common side effect of zinc.
Regional Outlook
The global Wilson disease drug market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Germany, France, Spain, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (Middle East & Africa and Latin America). Asia-Pacific is expected to grow significantly in the market during the forecast period owing to the significant incidence in the region.
North American region is proven to be the largest market for the global Wilson disease drug market. The growth is mainly augmented owing to the presence of leading market players in the North American region. Moreover, the rise in the number of patients with hereditary disorders, along with the rise in healthcare expenditure, enhances the market growth in the region. As per the US Department of Health & Human Services, the estimated number of people with Wilson's disease in the US may be between 3,000 to 30,000. There is a significant awareness among the US population regarding hereditary disorders, which in turn, is driving the growth of the market in the region.
Global Wilson Disease Drug Market Growth, by Region 2021-2028
Market Players Outlook
The major companies operating in the global Wilson disease drug market include Bausch Health Co. Inc., Nobelpharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., and Kadmon Holdings, Inc. The market players are contributing significantly to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, new product launches, and partnerships, to stay competitive in the market. For instance, in May 2022, Orphalan SA declared US FDA approval of Cuvrior, a new salt of trientine (trientine tetrahydrochloride). Cuvrior is approved for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Penicillamine is currently approved as a first-line treatment of Wilson’s disease in the US with about one-third of patients developing intolerance. Orphalan commercializes its trientine tetrahydrochloride product in Europe under the name of Cuprior and expects to launch Cuvrior, which has been granted Orphan Drug Designation by the FDA, in the US by early 2023. The approval follows the New Drug Application (NDA) submission for the company’s product in 2021.
Additionally, in August 2020, Dr Reddy’s Laboratories launched generic penicillamine capsules, to treat Wilson disease and cystinuria in the US market. penicillamine capsules are used by patients with severe, active rheumatoid arthritis, and the body failed to respond to an adequate trial of conventional therapy.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Wilson disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Recovery Scenario Of Global Wilson Disease Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight and Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Merck & Co., Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Bausch Health Co. Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Kadmon Holdings, Inc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.3.5. Recent Developments
3.1.4. Nobelpharma Co. Ltd.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Teva Pharmaceutical Industries Ltd.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.1.5.5. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Wilson Disease Drugs Market by Drug Type
4.1.1. Chelating Agents
4.1.2. Zinc
4.1.3. Tetrathiomolybdate
4.2. Global Wilson Disease Drugs Market by Route of Administration
4.2.1. Oral
4.2.2. Parenteral
4.2.3. Others
4.3. Global Wilson Disease Drugs Market by Distribution Channel
4.3.1. Hospital Pharmacy
4.3.2. Retail Pharmacy
4.3.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AstraZeneca plc
6.2. Deep Genomics
6.3. DepYmed Inc.
6.4. Dr. Reddy’s Laboratories Ltd.
6.5. Lupin Ltd.
6.6. Orphalan SA
6.7. Pfizer Inc.
6.8. Ultragenyx Pharmaceutical Inc.
6.9. Vivet Therapeutics
1. GLOBAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CHELATING AGENTS FOR WILSON DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ZINC FOR WILSON DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL TETRATHIOMOLYBDATE FOR WILSON DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
6. GLOBAL ORAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL PARENTRAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL OTHER ROUTE OF ADMINISTRATION FOR WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
10. GLOBAL WILSON DISEASE DRUGS FROM HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL WILSON DISEASE DRUGS FROM RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL WILSON DISEASE DRUGS FROM OTHER DISTRIBUTION CHANNELS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. NORTH AMERICAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
16. NORTH AMERICAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
17. NORTH AMERICAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
18. EUROPEAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. EUROPEAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
20. EUROPEAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
21. EUROPEAN WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
26. REST OF THE WORLD WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
27. REST OF THE WORLD WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE , 2021-2028 ($ MILLION)
28. REST OF THE WORLD WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2021-2028 ($ MILLION)
29. REST OF THE WORLD WILSON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL WILSON DISEASE DRUGS MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
2. GLOBAL CHELATING AGENTS FOR WILSON DISEASE MARKET SHARE BY REGION, 2021 VS 2028 (%)
3. GLOBAL ZINC FOR WILSON DISEASE MARKET SHARE BY REGION, 2021 VS 2028 (%)
4. GLOBAL TETRATHIOMOLYBDATE FOR WILSON DISEASE MARKET SHARE BY REGION, 2021 VS 2028 (%)
5. GLOBAL WILSON DISEASE DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
6. GLOBAL ORAL WILSON DISEASE DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL PARENTERAL WILSON DISEASE DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL OTHER ROUTE OF ADMINISTRATION FOR WILSON DISEASE DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL WILSON DISEASE DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
10. GLOBAL WILSON DISEASE DRUGS FROM HOSPITAL PHARMACY MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL WILSON DISEASE DRUGS FROM RETAIL PHARMACY MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL WILSON DISEASE DRUGS FROM OTHER DISTRIBUTION CHANNELS MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL WILSON DISEASE DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. US WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. UK WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. GERMANY WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF ASIA-PACIFIC WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD WILSON DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
